Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt

Journal of Infection and Public Health

Volumn 2, Issue 2, 2009, Pages 74-80

  Earhart, Kenneth C ^a   Elsayed, Nasr M ^b   Saad, Magdi D ^a   Gubareva, Larisa V ^c   Nayel, Ahmed ^b   Deyde, Varough M ^c   Abdelsattar, Ali ^b   Abdelghani, Ahmad S ^b   Boynton, Bruce R ^a   Mansour, Moustafa M ^a   Essmat, Hala M ^b   Klimov, Alexander ^c   Shuck Lee, Deidra ^a   Monteville, M R ^a   Tjaden, Jeffrey A ^a  

^a US Naval Medical Research Unit No 3 Egypt   (Egypt)

^b MINISTRY OF HEALTH   (Egypt)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

A(H5N1); Egypt; Influenza A virus; Neuraminidase inhibitors; Oseltamivir resistance

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EGYPT; GENE MUTATION; GENE SEQUENCE; HUMAN; INFLUENZA VIRUS A H5N1; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; EGYPT; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, VIRAL; YOUNG ADULT;

EID: 67349090612     PISSN: 18760341     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jiph.2009.04.004     Document Type: Article

References (29)

1. Yingst S.L., Saad M.D., and Felt S.A. Qinghai-like A(H5N1) from domestic cats, northern Iraq. Emerg Infect Dis 12 August (8) (2006) 1295-1297
2. World Health Organization (WHO). Clinical management of human infection with avian influenza A(H5N1) virus: http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf.
3. Aoki F.Y., Boivin G., and Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy 12 (2007) 603-616
4. Lackenby A., Hungnes O., Dudman S.G., et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 13 (2008) pii: 8026
5. Dharan N.J., Gubareva L.V., Meyer J.J., et al. Infection with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301 March (10) (2009) 1034-1041
6. Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H5N1), South Africa. EID 2008 11 November;14(11):1809-10.
7. World Health Organization. Influenza A(H5N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere: http://www.who.int/csr/disease/influenza/H1N1webupdate20090318%20ed_ns.pdf.
8. de Jong M.D., Tran T.T., Truong H.K., et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353 December (25) (2005) 2667-2672
9. Le Q.M., Kiso M., Someya K., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 October (7062) (2005) 1108
10. Spackman E., Senne D.A., Myers T.J., et al. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J. Clin. Microbiol. 40 September (9) (2002) 3256-3260
11. Payungporn S., Chutinimitkul S., Chaisingh A., et al. Single step multiplex real-time RT-PCR for A(H5N1) influenza A virus detection. J Virol Methods 131 February (2) (2006) 143-147
12. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp 41 (1999) 95-98
13. Kumar S., Tamura K., and Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5 June (2) (2004) 150-163
14. Wetherall N.T., Trivedi T., Zeller J., et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41 February (2) (2003) 742-750
15. Gubareva L.V., Webster R.G., and Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Research 53 January (1) (2002) 47-61
16. Aymard-Henry M., Coleman M.T., Dowdle W.R., et al. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ 48 2 (1973) 199-202
17. Kiso M., Mitamura K., Sakai-Tagawa Y., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 August (9436) (2004) 759-765
18. Gubareva L.V., Kaiser L., Matrosovich M.N., et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183 4 (2001) 523-531
19. Bright R.A., Medina M.J., Xu X., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 October (9492) (2005) 1175-1181
20. Bright R.A., Shay D.K., Shu B., et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 Febrauary (8) (2006) 891-894
21. Deyde V.M., Xu X., Bright R.A., et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196 July (2) (2007) 249-257
22. Barr I.G., Hurt A.C., Deed N., et al. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res 75 (2007) 173-176
23. Saito R., Li D., and Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005-2006. N Engl J Med 356 (2007) 312-313
24. Cheung C.L., Rayner J.M., Smith G.J., et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193 (2006) 1626-1629
25. Babu Y.S., Chand P., Bantia S., et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43 19 (2000) 3482-3486
26. Treanor J.J., Hayden F.G., Vrooman P.S., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283 8 (2000) 1016-1024
27. Russell R.J., Haire L.F., Stevens D.J., et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 7107 (2006) 45-49
28. Smith B.J., Kimm-Breshkin J.L., McDonald M., et al. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 45 11 (2002) 2207-2212
29. Rayner CR, Chanu P, Gieschke R, et al. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharm,. 2008. doi:10.1177/0091270008320317.